JP Morgan Chase
CRBP icon

JP Morgan Chase’s Corbus Pharmaceuticals CRBP Stock Holding History

JP Morgan Chase’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-983
Closed -$6.78K – 7439
2025
Q2 		$6.78K Sell
983
-4,742
-83% -$34.4K ﹤0.01% 6374
2025
Q1 		$30.4K Buy
5,725
+448
+8% +$3.96K ﹤0.01% 6029
2024
Q4 		$62.3K Sell
5,277
-230
-4% -$3.86K ﹤0.01% 5933
2024
Q3 		$114K Buy
5,507
+1,172
+27% +$60K ﹤0.01% 5645
2024
Q2 		$196K Sell
4,335
-57,219
-93% -$2.41M ﹤0.01% 5174
2024
Q1 		$2.42M Buy
61,554
+61,011
+11,236% +$1.5M ﹤0.01% 3702
2023
Q4 		$3.28K Sell
543
-1,163
-68% -$6.24K ﹤0.01% 6637
2023
Q3 		$11.5K Buy
1,706
+1,519
+812% +$10.5K ﹤0.01% 6215
2023
Q2 		$1.47K Sell
187
-6
-3% -$54 ﹤0.01% 6394
2023
Q1 		$1K Sell
193
-1,254
-87% -$5.49K ﹤0.01% 6503
2022
Q4 		$5K Sell
1,447
-19
-1% -$73 ﹤0.01% 6151
2022
Q3 		$7K Sell
1,466
-323
-18% -$2.28K ﹤0.01% 6020
2022
Q2 		$14K Sell
1,789
-1,649
-48% -$15.9K ﹤0.01% 5963
2022
Q1 		$55K Sell
3,438
-148
-4% -$1.96K ﹤0.01% 5763
2021
Q4 		$66K Buy
3,586
+2,433
+211% +$65.9K ﹤0.01% 5845
2021
Q3 		$35K Sell
1,153
-5,089
-82% -$201K ﹤0.01% 5925
2021
Q2 		$342K Sell
6,242
-4,191
-40% -$233K ﹤0.01% 4940
2021
Q1 		$617K Buy
10,433
+1,797
+21% +$118K ﹤0.01% 4549
2020
Q4 		$323K Buy
8,636
+7,608
+740% +$284K ﹤0.01% 4615
2020
Q3 		$61K Buy
1,028
+252
+32% +$45.6K ﹤0.01% 4886
2020
Q2 		$195K Sell
776
-7,069
-90% -$1.43M ﹤0.01% 4272
2020
Q1 		$1.23M Buy
7,845
+1,819
+30% +$308K ﹤0.01% 3283
2019
Q4 		$987K Buy
6,026
+4,736
+367% +$700K ﹤0.01% 3870
2019
Q3 		$188K Buy
1,290
+648
+101% +$113K ﹤0.01% 4659
2019
Q2 		$132K Buy
642
+100
+18% +$21.4K ﹤0.01% 4825
2019
Q1 		$113K Buy
542
+117
+28% +$25.8K ﹤0.01% 4845
2018
Q4 		$74K Buy
425
+40
+10% +$7.98K ﹤0.01% 4951
2018
Q3 		$87K Buy
385
+47
+14% +$7.6K ﹤0.01% 5003
2018
Q2 		$51K Buy
338
+8
+2% +$1.45K ﹤0.01% 5072
2018
Q1 		$60K Sell
330
-19
-5% -$4.27K ﹤0.01% 4758
2017
Q4 		$74K Buy
+349
New +$74.7K ﹤0.01% 4768
2016
Q3 		– Sell
-33
Closed -$3K – 4577
2016
Q2 		$3K Buy
+33
New +$2.59K ﹤0.01% 4535

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
EAM
Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

JP Morgan Chase's CRBP Position: Q3 2025 in Review

JP Morgan Chase sold out of Corbus Pharmaceuticals (CRBP) in Q3 2025, closing a stake of 983 shares — an estimated $6.78K sold.

JP Morgan Chase first reported a position in CRBP in Q2 2016 and held it in 32 quarters. The position peaked at $2.42M in Q1 2024. 81 funds tracked by Wall St. Rank hold CRBP as of Q3 2025.

  • JP Morgan Chase reported no remaining Corbus Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • JP Morgan Chase sold 983 Corbus Pharmaceuticals shares in Q3 2025, an estimated $6.78K.
  • JP Morgan Chase first reported a position in Corbus Pharmaceuticals in Q2 2016 and held it in 32 quarters.
  • JP Morgan Chase's Corbus Pharmaceuticals position peaked at $2.42M in Q1 2024.
  • 81 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2025.

Based on JP Morgan Chase's 13F filing for Q3 2025, filed 7 Nov 2025.